Select a community
All Communities
Home > Community Treatment Reports > Ondansetron Treatment Report
What is Ondansetron?

Ondansetron is an antiemtic drug used to prevent nausea and vomiting following chemotherapy, radiation therapy, or surgery.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Nausea 21 1
Nausea/Vomiting 4 1
Other 4 1
To control nausea 1 0
General health 1 0
nausea, dizziness 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
1 33%
Moderate
0 0%
Mild
1 33%
None
1 33%

Most commonly reported side effects

Somnolence
1 33%
Grogginess
1 33%
  • Mild
  • Moderate
  • Severe

Dosages

  2 mg as needed 2mg/mL as needed 4 mg as needed 4mg as needed 8mg as needed as needed daily 4 mg daily 8 mg daily 16 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2 10 Number of Patients: 10 8 Number of Patients: 8 1 Number of Patients: 1 1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 4 Number of Patients: 4  

Stop Reasons

Why Patients Stopped Taking Ondansetron (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other
4 80% Other: 80%
Did not seem to work
1 20% Did not seem to work: 20%

See all 5 patients who’ve stopped taking Ondansetron

Currently Taking Ondansetron

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
7
5
0
4
4

Stopped Taking Ondansetron

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
3
2
0
0
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
2 67%
Usually
1 33%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
3 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.